February 27, 2023Open Access
View Full PaperRandomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure
Key Result
Mesenchymal precursor cells may improve outcomes in heart failure patients, particularly those with inflammation, despite negative primary and secondary endpoints.
Structured PICO
Does targeted transendocardial mesenchymal precursor cell therapy improve outcomes in patients with heart failure?
P
Population
Patients with heart failure
I
Intervention
Targeted transendocardial mesenchymal precursor cell therapy
Targeted transendocardial mesenchymal precursor cell therapy did not meet primary or secondary endpoints in heart failure patients, though exploratory analyses suggest potential benefit in those with inflammation.
Main Result
Absolute Event Rate: 0% vs 0%
Abstract
The primary and secondary endpoints of the trial were negative. Positive signals in prespecified, and post hoc exploratory analyses suggest MPCs may improve outcomes, especially in patients with inflammation.